| Literature DB >> 30262506 |
Ivan Marquez-Rodas1, María Angela Aznar2, Antonio Calles3, Ignacio Melero2,4.
Abstract
Intratumoral immunotherapy can potentially modulate the tumor microenvironment (TME) and potentiate the effects of concomitant or sequential systemic immunotherapies. Intratumoral administration of different Toll-like receptor agonists, including TLR4, can potentiate these effects through innate and adaptive immunity connection.See related article by Bhatia et al., p. 1185. ©2018 American Association for Cancer Research.Entities:
Mesh：
Substances：
Year: 2018 PMID： 30262506 DOI： 10.1158/1078-0432.CCR-18-2690
Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531